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Abstract 
Hypertension and Type 2 diabetes mellitus (T2DM) coexist frequently and both increase 
the incidence of cardiovascular disease. Recently developed drugs in the GLP-1 receptor 
agonists class and SGLT2 inhibitor class have been noted to have hypotensive actions (Katayama 
et al., 2018). Controlling blood pressure and glucose are increasingly important for the treatment 
of diabetes accompanied by hypertension. A case report was analyzed and the topic of sodium–
glucose cotransporter 2 (SGLT2) inhibitors compared to glucagon-like peptide-1 (GLP-1) 
receptor agonists for the selection of a second line treatment for T2DM patients with 
hypertension was formulated. A literature review was done using databases such as CINAHL and 
PubMed. The literature in these articles and guidelines outlined below demonstrates the wide 
variety of benefits of both SGLT2 inhibitors and GLP-1 agonists within the T2DM population. 
While both pharmacological classes have benefits, they also have contradictions. SGLT2 
inhibitors and GLP-1 receptor agonists independently improve cardiovascular outcomes and do 
so by separate mechanisms. Guidelines recommend due to the unique side effects and benefits of 
each medication class the health care provider decision requires an individualized approach to 
select the appropriate medication class.  
Background 
Type 2 diabetes mellitus (T2DM) and hypertension coincide frequently. According to 
Bailey & Marx (2019) “among individuals with T2DM nearly 40% have hypertension at the time 
of DM diagnosis” (p.1). Even if blood pressure was initially normal, it often rises with the 
advancement of diabetic nephropathy, resulting in hypertension (Katayama et al., 2018). 
Cardiovascular related adverse effects are approximately double within the T2DM population. 
The cardiovascular events are related to microvascular and macrovascular damage which result 
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in myocardial infarction, stroke, and heart failure (Bailey & Marx 2019). Almost half of T2DM 
patients will die from a MI (Scheen, 2018). Reducing the risk for major adverse cardiac events is 
now directed from a comprehensive approach beyond glucose control. Since 2008 and 2012 the 
Food and Drugs Administration (FDA) and the European Medicines Agency (EMA) have 
mandated that any new medication used for the treatment of T2D must have a cardiovascular 
outcome trial to demonstrate its safety and MACE (Sinha & Ghosal, 2019).  
Comparing hypertension in diabetic patients to normotensive non-diabetics, “the rate of 
onset of cardiovascular disease is 5–7 times higher in diabetic patients with hypertension” 
(Katayama et al., 2018, p.216). Hyperglycemia elevates blood pressure within diabetes due to 
arterial stiffness, sodium retention, leading to a volume expansion and a greater volume of 
exchangeable sodium (Briasoulis et al., 2018). Clinical trials have demonstrated that with 
decreasing blood pressure, there is an improvement of hyperglycemia and reduction of the 
micro- and macrovascular complications of diabetes. Early treatment of hypertension and 
diabetes will prevent and delay the progression of cardiovascular disease and potential diabetic 
nephropathy (Katayama et al., 2018).  
Recent pharmacological advancement in treatment of T2DM has demonstrated many 
cardiovascular benefits including the success of intensive blood pressure control for reducing the 
micro- and macrovascular complications of diabetes (Briasoulis et al., 2018). The two 
pharmacological categories that have seen these results are the SGLT2 inhibitors and the GLP-1 
receptor agonists. SGLT2 inhibitor studies have shown results in sustained systolic and diastolic 
blood pressure reduction and meta-analysis data does note GLP-1 receptor agonists have a 
beneficial effect on systolic blood pressure in patients with T2DM (Gurgle et al., 2016). Both 
SGLT2 inhibitors and GLP-1 receptor agonists can improve glycemic control and reduce blood 
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pressure, body weight, and major adverse cardiac outcomes. However, it is not obvious which of 
the two classes should be preferred in a T2DM patient with established cardiovascular disease 
(Scheen, 2018). 
This literature review will incorporate a case report describing a woman in 
her late fifties who has a history of hypertension and T2DM. She subsequently presented to her 
primary provider for a fever. It was not known at the time if she had been adherent to her current 
medications. During the visit she was diagnosed with cellulitis and probable sepsis. Treatment 
was initiated in the emergency room. The purpose of this review is to compare the clinical trials 
and real-world effectiveness of SGLT2 inhibitors compared to GLP-1 agonists, related to their 
effectiveness within the T2DM-HTN population.  
Case Report 
J.B. was a 58-year-old obese female who presented to the clinic accompanied by her 
sister for fever, chills, and confusion for one day. The patient had a past medical history of Type 
2 diabetes, hypertension, and hyperlipidemia. Patient reports a fever that has been present for one 
day for which she has been using Ibuprofen (last dose within 2-3 hours). She states that despite 
using ibuprofen the fever remains elevated with a measured fever of 104.7 F upon clinic visit. 
She states her family had concerns of her being confused within the past day. She describes the 
confusion as ‘forgetfulness’ and does not feel it is a concern. She does report forgetfulness, mild 
fatigue, and feeling chilled requiring blankets. There are no known ill contacts at home.  
She denies cough, wheezing, shortness of breath, chest pain, palpitations, abdominal 
pain, nausea, vomiting, diarrhea, polyuria, dysuria. She denies headache, change in vision, neck 
pain, dizziness or lightheadedness. She reports no swelling, numbness/tingling in her extremities, 
sores on her feet.  She denies concerns of confusion and or forgetfulness.  
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J.B. is currently on medication including the following: ezetimibe 5 mg tablet, metoprolol 
50 mg two times daily, Lisinopril 10 mg daily, Metformin 1000 mg daily, Fish oil 1000 mg daily, 
Zocor 80 mg daily, Aspirin 325mg daily. She reports no known allergies, no current tobacco use, 
states she quit smoking in 2002. She is currently up to date on immunizations including influenza 
and pneumonia. She denies recent hospitalizations or antibiotic use. She has a surgical history of 
tubal ligation > 10 years. Her family history does include type 2 diabetes and cardiovascular 
disease in her father. 
A complete physical examination was performed after obtaining the patient’s 
history. J.B.’s vital signs included: height 5’5”, weight 118 kg (260 lbs), a BMI of 43.4 kg/m, 
blood pressure 194/83, pulse 119, respirations 14, temperature 104.7 F, O2 93% on room air. 
Obese female with well-kept appearance is resting quietly in clinic room. She does not appear to 
be in distress. Her skin is pale, hot, and diaphoretic. She is awake, alert and oriented to self, 
place, and time. She answers questions appropriately. Head is atraumatic and the neck is supple 
without masses. The thyroid was nonpalpable and no lymphadenopathy is palpated. There is no 
JVD observed or carotid bruit found. Red reflex present bilaterally, with her pupils equal, round 
and reactive to light and fundi were clear and with no arteriovenous nicking or retinopathy. Her 
EOM’s are intact. The ears are symmetrical, no tenderness or discharge, normal tympanic 
membranes with positive light reflex. Patent nares with moist and pink mucosa. Her lungs were 
clear to auscultation, no wheezes, crackles or rhonchi noted, with even and unlabored 
respirations. S1 and S2 were heard, heart rate and rhythm were regular with no extra heart 
sounds, murmurs, or gallops. Abdomen was globulous, soft, nondistended, nontender. Bowel 
sounds were present in all four quadrants. No CVA tenderness was noted on percussion. The 
lower left extremity has edema with significant erythema and tenderness to the soft tissues 
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measuring an area of 8 cm x 6 cm. Distal pulses are 2+. Musculoskeletal system reveals no 
obvious deformity with strength equal bilaterally. Gait was observed to be steady on arrival. 
Cranial nerves I-XII are grossly intact.  
Differential diagnosis  
Cellulitis, MRSA rule out, sepsis, Chills with fever, Uncontrolled Type 2 diabetes mellitus, 
Uncontrolled Essential hypertension. 
Labs/Imaging  
Labs were obtained during the office visit CBC, CRP, CMP, lactic acid, and ESR and were as 
follows: WBC 12.5 K/uL*, CRP 144.4 mg/dL*, glucose 266 mg/dL*, sodium 132 meq/L*, 
chloride 94 meq/L*, CO2 20 meq/L*, anion gap 22 meq/L*, lactic aicd 4.4 mmol/L*, ESR 57 
mm/Hr*. There was no imaging obtained at that time.  
Plan  
Based on J.B.’s medical history, physical exam of new skin infection, high temperature 
despite recent antipyretics, increased heart rate, and decreased oxygen saturation this patient was 
sent to the emergency department for further evaluation of potential sepsis. Based on J.B.’s 
medical history, physical exam of new skin infection, high temperature despite recent 
antipyretics, increased heart rate, and decreased oxygen saturation this patient was sent from the 
clinic to the emergency department for further evaluation of potential sepsis. Hospitalization was 
required for IV fluids, antibiotics, wound cultures with sensitivity, monitoring of blood glucose 
and renal function.  
Following hospitalization, JB will be seen in 1-2 weeks after hospital discharge and then 
a minimum of every 3 months until stabilized. We will coordinate care with the diabetes 
educator, dietician, and wound care specialists. Receiving the proper education from these 
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specialties will provide her with the tools to improve her health and reduce complications. HgB 
A1C and BMP should be drawn every 3 months to monitor glucose control and renal function. 
Regulation of glucose and hypertension is prudent to reducing cardiovascular risk. She may 
require addition of an SGL2 inhibitor and/or GLP-1 receptor agonist to current medication 
regime in order to obtain tighter glucose control. Weight loss and proper nutrition can also help 




According to the American Diabetes Association (ADA) and the European Association 
for the Study of Diabetes (EASD) an update to the 2018 recommendations was requested due to 
the research findings in 2019 of cardiovascular outcome trials (Buse et al., 2020). There is a 
fundamental change in T2DM management, moving from a goal of glucose control to an 
objective of cardiovascular and renal protection (Bailey & Marx 2019). Newer diabetes mellitus 
agents such as SGLT2 inhibitors and GLP-1 receptor agonists have been demonstrated to have 
cardio-protective effects. The impact of tight blood pressure control with persons of T2DM and 
hypertension remains to be interpreted (Buse et al., 2020). Again, this literature review is focused 
on exploring the evidenced behind the selection of a second line treatment for T2DM patients 
with hypertension.  
Literature Search  
A literature review was performed to gather evidence and articles relevant to the use of a 
SGLT2 inhibitor compared to a GLP-1 receptor agonist in diabetic patients with hypertension 
and cardiovascular risk. Literary sources were gathered using the PubMed and CINAHL 
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(Cumulative Index to Nursing & Allied Health), provided from the UND School of Medicine and 
Health Sciences online resources. 
 A variety of keywords were used to search for sources including the following: “SGLT2 
inhibitors”, “GLP-1 receptor agonists”; “hypertension”, “cardiac outcomes”, “trial outcomes.” 
Articles used for the analysis of the literature were no more than five years old and were limited 
to English text only. The intention of these limitations was to provide evaluation that utilized 
current and relevant information. A total of 258 articles resulted from a search within PubMed 
using “SGLT2 inhibitors” and “GLP-1 receptor agonists.” To narrow this large number of results, 
a search then included the key words “cardiac outcome” and which resulted in a selection of 41 
articles. A total of 7 articles were reviewed within the search criteria limitations that were put in 
place and were used throughout the literature review process. An additional search in PubMed 
was performed using “SGLT2 inhibitors”, “GLP-1 receptor agonists”; “hypertension”, and a total 
of 2 articles were reviewed and selected for further literature evaluation. The database of 
CINAHL was then reviewed for further articles related to “SGLT2 inhibitors”, “GLP-1 receptor 
agonists”; “trial outcomes”, a total of 7 articles were resulted and 2 articles were selected and 
were utilized in the literature review. A total of 11 articles were finally selected for the literature 
review of this paper.  
Synthesis of Current Literature   
SGLT2 inhibitors are one of the first anti-hyperglycemics to demonstrate significant 
cardiovascular benefits in multiple cardiovascular outcomes trials. The primary mechanism of 
action within SGLT2 inhibitors is the inhibition of sodium-glucose cotransporter 2 in the kidneys 
to prevent reabsorption of glucose and facilitate its excretion in urine (Nagahisa & Saisho, 2019). 
The beneficial cardiovascular outcomes were subsequently identified within multiple different 
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trials. The mechanisms of action for cardiovascular benefits are osmotic diuresis leading to 
improved hemodynamic function, reduction of blood pressure, beneficial weight loss, and a shift 
in body fuel with ketosis (Dhindsa et al., 2019). SGLT2 inhibitors decrease blood pressure 
through osmotic diuresis. Other factors to be noted is a reduction in arterial stiffness and 
improvement in endothelial dysfunction which was been demonstrated in recent studies (Lim et 
al., 2018). 
 GLP-1 is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon 
secretion, inhibits gastric emptying, and reduces appetite and food intake. GLP-1 receptor 
agonists initially were developed as glucose-lowering medications. They since have been 
associated with multidimensional actions (Sinha & Ghosal, 2019).  Through animal studies and 
small clinical studies, GLP1-receptor agonists have been found to reduce inflammation in the 
vascular endothelium. This results in the improvement of endothelial function, plaque stability, 
blood flow and platelet aggregation They have positively lowered glucose, body weight, and 
recent studies have shown positive implications of reducing blood pressure (Garg et al., 2019)  
The three largest CVD outcome trials of SGLT2 inhibitors are Empagliflozin 
Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus (EMPA-REG OUTCOME), 
Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, and the Dapagliflozin 
Effect on Cardiovascular Events (DECLARE-TIMI) 58 trial (Garg et al., 2019). In EMPA-REG 
OUTCOME the study resulted with a 38% reduction in cardiovascular mortality, 32% reduction 
in all-cause mortality, and a 35% reduction in heart failure hospitalizations were observed in 
those blood randomized to empagliflozin (Dhindsa et al., 2019). The use of empagliflozin 
decreased blood pressure 2-3 mmHg in the treatment group (Lim et al., 2018). The CANVAS 
similarly mimicked the EMPA-REG OUTCOME results and showed a 33% reduction in heart 
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failure hospitalizations in those patients randomized to canagliflozin (Dhindsa et al., 2019). 
Canagliflozin therapy decreased systolic blood pressure by 3.93 mmHg and diastolic blood 
pressure by 1.39 mmHg (Lim et al., 2018). 
DECLARE-TIMI 58 trials had available data on left ventricular ejection fraction which 
marked the importance of this medication class in heart failure. Dapagliflozin reduced 
hospitalizations for heart failure in patients with and without reduced ejection fractions and 
reduced cardiovascular disease death (Dhindsa et al., 2019). Dapagliflozin and ipragliflozin 
treatment were noted to have a 2-5 mmHg reduction in blood pressure (Lim et al., 2018). 
Several trials have been performed using GLP-1 agonists in patients with T2DM with 
either established or elevated risk factors for cardiovascular disease. These trials include: 
Liraglutide Effect and Action in Diabetes, Evaluation of Cardiovascular Outcomes Results-A 
Long-Term Evaluation (LEADER), Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-
6), and HARMONY (Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes 
and Cardiovascular Disease) (Dhindsa et al., 2019). The LEADER trial’s three-point major 
adverse cardiac events were reduced by 13% in the liraglutide group, with a 22% reduction in 
cardiovascular death and a 15% reduction in total mortality (Bailey & Marx 2019). The 
LEADER trial hallmarked liraglutides significant reduction in all-cause mortality predominantly 
driven by a reduction in cardiovascular deaths (Nagahisa & Saisho, 2019). 
The SUSTAIN-6 trial semaglutide group compared to the placebo demonstrated a 
significant reduction in major adverse cardiac events by 26% after 2.1 years with a 39% 
reduction of non-fatal stroked (Bailey & Marx 2019). The trial also demonstrated a 36% 
reduction in the risk of new or worsening nephropathy which subsequently helps decrease blood 
pressure (Nagahisa & Saisho, 2019). The trial noted a mean reduction of 2.6 mmHg in systolic 
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blood pressure (Garg et al., 2019). The HARMONY trial demonstrated major adverse cardiac 
events were reduced by 22% and significant reduction in myocardial infarction (Dhindsa et al., 
2019).  
A thorough review of the literature revealed that previous trials of diabetic medications 
such as the SGLT2 inhibitors and GLP-1 receptor agonists goal was glucose control. Most trials 
were not driven to assess blood pressure outcomes (Gurgle et al., 2016). Over the past decade the 
treatment for patients with T2DM with established or at a high risk for cardiovascular disease has 
entirely changed to cardiovascular prevention and reduction, and ultimately decreasing major 
adverse cardiac events (Garg et al., 2019). The current studies of SGLT2 inhibitors and GLP1 
receptor agonists have proven their efficacy to reduce major adverse cardiac events. Blood 
pressure control is a crucial factor for cardiovascular complications which makes  
hypertension one of most important risk factor for arteriosclerosis in diabetics (Scheen, 2018). 
Recently developed GLP-1 receptor agonists and SGLT2 inhibitors have hypotensive 
actions, making them ideal for use in diabetics with hypertension (Katayama et al., 2018). The 
literature review confirms that treatment with SGLT2 inhibitors results in sustained systolic and 
diastolic blood pressure reduction (Briasoulis et al., 2018). The presumed factors for the 
decreased blood pressure are part osmotic diuresis and glucose excretion; followed by natriuresis 
and reduced intravascular volume, ameliorated arterial elasticity, and reduced cardiac preload 
and afterload (Nagahisa & Saisho, 2019). Literature also confirmed SGLT2 inhibitors offer a 
renal protective effect with significant reductions in the onset and or progression of nephropathy 
with empagliflozin and canagliflozin (Bailey & Marx 2019).  Lastly, it was confirmed the use of 
SGLT2 inhibitors in patients with T2DM resulted in a reduction of 3 to 6 mmHg reduction in 
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systolic blood pressure and a 0 to 2 mmHg drop in diastolic blood pressure (Briasoulis et al., 
2018).  
With all medications there are side effects and risks and benefits to be weighed. The 
review from Dhindsa et al., (2019) discussed that the SGLT2 inhibitors have reported a 5% 
occurrence of candida vaginitis in women and a 10% of balanitis in men. Canagliflozin in the 
CANVAS Program was associated with an increased risk of lower limb amputation compared to 
the placebo. It is important to emphasize overall amputation risk was correlated with a prior 
history of amputation at baseline (Nagahisa & Saisho, 2019). The literature review from Buse et 
al., (2020) discussed that in the CREDENCE trial with canagliflozin although the risk of 
amputation was higher overall than in other SGLT2 inhibitors no significant increase in risk was 
observed with canagliflozin compared to the placebo.  
Results of a meta-analysis of clinical trials and studies showed GLP-1 receptor agonists 
positively reduce blood pressure and body weight, have an anti-atherothrombotic effect, and 
have few episodes of hypoglycemia (Dhindsa et al., 2019). Garg et al., (2019) confirmed that 
GLP-1 receptor agonists additionally decrease atherosclerosis, myocardial ischemia, 
inflammation, endothelial dysfunction, and blood pressure. In reviewing the cardiovascular 
outcomes trials systolic blood pressure was noted to be between 0.8 and 2.6 mmHg less than the 
placebo group. The largest blood pressure difference was seen in the use of semaglutide in the 
SUSTAIN-6 trial, with an average reduction of 2.6 mmHg in systolic blood pressure, which may 
occur through increased renal excretion of sodium and endothelial vasodilation (Garg et al., 
2019). An additional meta-analysis by Sinha & Ghosal (2019) highlighted that the class of GLP-
1 receptor agonists reduce risk of atherosclerotic cardiovascular disease by cause a significant 
reduction in myocardial infarction and stroke. 
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Through the literature review, in the SUSTAIN-6 trial with the GLP-1 receptor agonist 
semaglutide, the common side effects were nausea, vomiting, and diarrhea (Dhindsa et al., 2019). 
The LEADER trial noted with the use of liraglutide, there was a significant increase in acute 
gallstones and acute cholecystitis. The SUSTAIN-6 trial also showed that semaglutide was 
associated with increased retinopathy complications but was largely in those individuals with 
retinopathy at baseline (Nagahisa & Saisho, 2019). An additional animal trial discussed that 
GLP-1 receptor agonists have been associated with medullary thyroid cancer and for now, should 
be avoided or used in caution with any history of medullary thyroid cancer or multiple endocrine 
neoplasia (Dhindsa et al., 2019). 
In providing recommendations to patients regarding drug therapy, providers should 
engage in shared decision making and must balance drug efficacy with potential side effects. 
SGLT2 inhibitors and GLP-1 receptor agonists are the first anti-hyperglycemic to demonstrate 
significant cardiovascular benefit and hypotensive properties. Both medication classes are 
indicated for T2DM-HTN patients. Given the side effects and benefits from both agents the 
appropriate selection for reduction of blood pressure and cardiovascular risk reduction requires 
an individualized approach.  
Learning Points 
• SGLT2 inhibitors and GLP-1 receptor agonists are the first anti-hyperglycemic to 
demonstrate significant cardiovascular benefit and hypotensive properties. 
•  Given the side effects and benefits from both agents the appropriate selection for 
reduction of blood pressure and CV risk reduction requires an individualized approach. 
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• The cardiovascular benefits seen with both SGLT2 inhibitors and GLP-1 agonists make 
the prospect of combination therapy with these agents particularly appealing in patients 
with T2DM. 
• Given the results from recent studies the American Diabetes Association and the 
European Association for the Study of Diabetes, recommend that patients with T2DM 
and clinical cardiovascular disease with inadequate glucose control despite treatment with 
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